Cyto-Mine ® is the next-generation single cell analysis system that enables users to simplify, automate, and speed up their antibody discovery as well as cell line development workflows.

Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social ...

英国Sphere Fluidics公司的Cyto-Mine®微流控单细胞分析筛选平台可很好地胜任AbD工作流程。所有的工作最快在4周左右的时间即可完成。改善了抗体发现的实验流程，大大加快了抗体发现的步伐。

Providing ultra-high-throughput screening of single cell assays and antibody-producing cells as well as the ability to sort them, Cyto-Mine is ready for use. Sphere Fluidics has now successfully ...

Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024 ...

These milestones reflect the ongoing strategic focus on operational scale-up to address demand for the Company's Cyto-Mine ® platform and provide local specialized support. As North America ...

Cyto-Mine: single-cell-analysis technology reinventing therapeutic discovery Download PDF ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global ...